UCB (UCBJF) recently presented data from a phase III study evaluating two dosing regimens of Cimzia (certolizumab pegol). The study evaluated 200mg (two-weekly dosing) and 400mg (four-weekly dos ...
via Investopedia.com Headlines http://www.investopedia.com/stock-analysis/Zacks/DataPresentedbyUCBonCimzia-AnalystBlog.aspx
8233 Old Courthouse Rd Ste 330 Vienna V.A. 22182
Matt Sileno
The Intuitive Group Inc
No comments:
Post a Comment